Corticosteroid Induced Acute Symptomatic Sinus Bradycardia in a Postpartum Woman Treated for Multiple Sclerosis

Aisha Taiyeb¹, Sarah Alqurashi^1, and Hani Aggad¹

¹Neurology Department, King Abdallah Medical Complex, Jeddah 23816, Saudi Arabia

Cite this paper:
Aisha Taiyeb, Sarah Alqurashi and Hani Aggad. Corticosteroid Induced Acute Symptomatic Sinus Bradycardia in a Postpartum Woman Treated for Multiple Sclerosis. American Journal of Medical Case Reports. 2019; 7(3):46-51. doi: 10.12691/ajmcr-7-3-4

Abstract

Multiple sclerosis (MS) is one of the most common neurological disorders and causes of disability among young adults worldwide. Pulse steroid therapy is commonly used to treat the acute relapses of MS. Acute Sinus bradycardia has been reported as a side effect after administration of pulse dose steroid; most of the reported cases are asymptomatic. A case of acute symptomatic sinus bradycardia was reported after administration of pulse steroid in post-partum women with multiple sclerosis.

Keywords:
multiple sclerosis postpartum sinus bradycardia corticosteroid

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	(WHO), W.H.O. Neurological Disorders public health challenges 2007; Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf.
[2]	Bohlega, S., et al., Multiple sclerosis in the Arabian Gulf countries: a consensus statement. Journal of Neurology, 2013. 260(12): p. 2959-2963.
[3]	Goldenberg, M.M., Multiple sclerosis review. P & T: a peer-reviewed journal for formulary management, 2012. 37(3): p. 175-184.
[4]	Ghasemi, N., S. Razavi, and E. Nikzad, Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell journal, 2017. 19(1): p. 1-10.
[5]	Brust, J.C.M., CURRENT Diagnosis & Treatment Neurology, Second Edition (LANGE CURRENT Series) 2nd Edition. 2007, New York: Lange Medical Books/McGraw-Hill Medical.
[6]	Lyons, P.R., P.K. Newman, and M. Saunders, Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. Journal of neurology, neurosurgery, and psychiatry, 1988. 51(2): p. 285-287.
[7]	La Mantia, L., et al., Double-Blind Trial of Dexamethasone versus Methylprednisolone in Multiple Sclerosis Acute Relapses. European Neurology, 1994. 34(4): p. 199-203.
[8]	Sinha, A.B., A., Pulse Steroid Therapy. Indian J Pediatr, 2008. 75(10): p. 1057-1066.
[9]	Franchin, G. and B. Diamond, Pulse steroids: How much is enough? Autoimmunity Reviews, 2006. 5(2): p. 111-113.
[10]	Stroeder, J., C. Evans, and H. Mansell, Corticosteroid-induced bradycardia: Case report and review of the literature. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC, 2015. 148(5): p. 235-240.
[11]	Gardiner, P.V. and I.D. Griffiths, Sudden death after treatment with pulsed methylprednisolone. BMJ (Clinical research ed.), 1990. 300(6717): p. 125-125.
[12]	Kundu, A. and T.P. Fitzgibbons, Acute symptomatic sinus bradycardia in a woman treated with pulse dose steroids for multiple sclerosis: a case report. Journal of medical case reports, 2015. 9: p. 216-216.
[13]	Guillen, E.L., A.M. Ruiz, and J.B. Bugallo, Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. American Journal of Kidney Diseases, 1998. 32(2): p. e4.1-e4.3.
[14]	van der Gugten A1, B.M., Frenkel J., Glucocorticoid-associated Bradycardia. J Pediatr Hematol Oncol, 2008. 30(2): p. 172-5.
[15]	Taylor, M.R. and D. Gaco, Symptomatic Sinus Bradycardia After a Treatment Course Of High-dose Oral Prednisone. Journal of Emergency Medicine, 2013. 45(3): p. e55-e58.
[16]	Hsu, D.T., Steroids and Bradycardia: How Slow Can You Go? Journal of Pediatric Hematology/Oncology, 2008. 30(2).
[17]	Pudil, R. and Z. Hrncir, Severe bradycardia after a methylprednisolone “minipulse” treatment. Archives of Internal Medicine, 2001. 161(14): p. 1778-1779.
[18]	Akikusa, J.D., et al., Sinus Bradycardia After Intravenous Pulse Methylprednisolone. Pediatrics, 2007. 119(3): p. e778.
[19]	Schurmann, P., et al., Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Multiple Sclerosis and Related Disorders, 2014. 3(3): p. 408-412.
[20]	Széplaki G1, M.B., [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis]. Ideggyogy Sz., 2012. 30(65): p. 369-76.
[21]	Fazekas, F., et al., How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Frontiers in neurology, 2013. 4: p. 10-10.
[22]	Obinata, H. and T. Hla, Sphingosine 1-phosphate in coagulation and inflammation. Seminars in immunopathology, 2012. 34(1): p. 73-91.
[23]	Cannon, R.E., et al., Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proceedings of the National Academy of Sciences of the United States of America, 2012. 109(39): p. 15930-15935.
[24]	Lucas, K.G., D.L. Howrie, and C.K. Phebus, Cardiorespiratory Decompensation Following Methylprednisolone Administration. Pediatric Hematology and Oncology, 1993. 10(3): p. 249-255.
[25]	Avila-Ornelas, J., et al., The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. International journal of MS care, 2011. 13(2): p. 91-93.